Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

By Jessica Merrill 14 Nov 2022

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Datamonitor Healthcare

Datamonitor Healthcare's Top Research Reports

27 Nov 2020

HBW Insight

Sanofi's New Consumer Chief Identifies 'Untapped Potential' In Digital

By Tom Gallen 17 Nov 2020

Sanofi's recently-appointed Consumer Healthcare head Julie Van Ongevalle says she has identified "untapped potential" for the business to utilize "cutting edge digital platforms." Van Ongevalle revealed her early plans for Sanofi as it reported a drop in Q3 sales.

Scrip

Quick Listen: Scrip's Five Must-Know Things

By Ian Haydock 17 Nov 2020

Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.

Scrip

Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

By Mandy Jackson 17 Nov 2020

Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.

Scrip

Pfizer's Bourla Urges Patience As COVID-19 Vaccine Data Timeline Lags

By Jessica Merrill 17 Nov 2020

Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.

Scrip

Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results

By Andy Smith 29 Oct 2020

Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air

Scrip

Gilead’s Major Challenge Is Sustainable Model For Remdesivir

By Joseph Haas 01 May 2020

With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.

Scrip

Bayer Adds Up COVID-19 Pluses and Minuses In Q1

By Kevin Grogan 30 Apr 2020

Bayer has beaten analyst forecasts for the first quarter but says the uncertainties brought about by the coronavirus pandemic prevent it from issuing financial guidance for the full year.